Finasteride And Dutasteride May Reduce Melanoma Risk

This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.

Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.

In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.

In a population-based study, over 72,000 older men were examined, and dutasteride showed no increased risk of heart failure, myocardial infarction, or stroke compared to finasteride, as reported by the researchers.

This case report describes an atypical postfinasteride syndrome in a patient treated with both dutasteride and finasteride for androgenic alopecia, highlighting its multisystem involvement and irreversible nature.

This review discusses the comparative efficacy of dutasteride and finasteride for benign prostatic hyperplasia, reporting that while symptom improvements are similar, dutasteride may reduce prostate surgery risk and acute urinary retention more effectively.

This study reported a significant association between severe teenage acne and an increased risk of melanoma, potentially linked to androgen levels, though causation cannot be confirmed.

In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.

This review found dutasteride to be effective, safe, and well-tolerated for treating symptomatic BPH and provides expert commentary on its use, though the relationship with high-grade prostate cancer remains unclear.

In this study, dutasteride, but not finasteride, reduced high-grade PIN lesions more effectively in C57xFVB TRAMP mice, although both drugs increased the incidence of poorly differentiated prostate cancer.

This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.